A randomised parallel group study to compare transarterial particle embolism with percutaneous ethanol injection in patients with unifocal, small (<3cm), non-resectable hepatocellular carcinoma

Submission date	Recruitment status	Prospectively registered
30/09/2005	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2005	Completed	Results
Last Edited	Condition category	Individual participant data
26/10/2015	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Andrew K Burroughs

Contact details

Department of Liver Medicine & Transplantation Royal Free Hampstead NHS Trust Pond Street Hampstead London United Kingdom NW3 20G

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0256159469

Study information

Scientific Title

A randomised parallel group study to compare transarterial particle embolism with percutaneous ethanol injection in patients with unifocal, small (<3cm), non-resectable hepatocellular carcinoma

Study objectives

Which is the best treatment in terms of survival of patients diagnosed with unresectable unifocal hepatocellular carcinoma (HCC) less than 3 cm in diameter treated with percutaneous ethanol injection or transarterial particle embolisation?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised parallel-group study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Cancer: Liver

Interventions

Percutaneous ethanol injection or transarterial particle embolisation

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Ethanol

Primary outcome measure

Survival of patient after treatment of unresectable, unifocal, small (3 cm) hepatocellular carcinoma

Secondary outcome measures

Not provided at time of registration

Overall study start date

31/07/2003

Completion date

31/07/2006

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

185

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

31/07/2003

Date of final enrolment

31/07/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Royal Free Hampstead NHS Trust London United Kingdom NW3 2QG

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Government

Funder Name

The Royal Free Hampstead NHS Trust (UK)

Funder Name

NHS R&D Support Funding

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration